Ann: Pause in Trading, page-16

So the TH is as a result of the German regulatory authority 'BfArM' results to be announced.

The only contract ZLD have in Germany is an agreement signed in Sept last year with Adjupharm.
It's for a 5-yr period, minimum revenue of A$4m, co-branded, exclusively marketed by them and first rights of negotiation goes to them for further European distribution.
It's only for Zenivol and can be terminated with 30 days written notice if either party fails to perform.

The regulatory authority side of it is only to do with Adjupharm ...being the distributor.
It allows for reimbursement for the sales of Zenivol, if approved.
It's not very clear just who gets reimbursed, whether it be Adjupharm's customers, or Adjupharm themselves for selling at a reduced price.

On face value, the advantage ZLD could achieve from a positive outcome of this would obviously be an increase in revenue from Adjupharm based on THEIR enhanced sales IF the Gov approves a reimbursement program.

To date, I haven't seen any figures on sales, save for the agreement of A$98k in the 'first year'.
This to be followed by an average of A$975,000 p/a over the next 4yrs.

Remember, this is Revenue and no idea what Profit might be involved - imo, very little for the first 2yrs.
After that, who knows...

Then we have the elephant in the room (leaving 'insider' shennanigans aside) ...
The German Regulatory Authority could deny the application ...

Either way, the leaky ship will probably see the sp correcting backwards (imo) no matter what the result will be because I cannot see this warranting such an upward movement over the past few days - as nice as it's been to see.

They chose to establish the new base in the USA - probably the most lucrative market in the world for Hope & Zenivol per capita - yet, if they're knocking on doors for business there, it looks like potential clients can see them coming and shut up shop. They wanted to play the numbers game but can't count.